A Contiguous, Sequential Phase I/II Imaging Study of 18F-fluoro-3'-L-fluorothymidine (18F-FLT)in Patients With Known or Suspected Carcinoma of the Lung, Breast, Renal Cell, Pancreas, or Brain, and With Gastrointestinal Malignancies, Neuroendocrine Tumours or Lymphoma
Clinical trial is a combined Phase I/II imaging, open label, single site study in patients
with known or suspected carcinoma of the lung, breast, renal cell, pancreas or brain, and
with gastrointestinal malignancies, neuroendocrine tumours, or lymphoma. One 18F-FLT PET
scan will be performed in 10 Phase I patients, and pre-injection and post-imaging blood work
and vital signs will be collected. Up to 5 18F-FLT PET scans will be performed in 170 Phase
II patients.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Phase I: to determine the safety of 18 F-FLT.
3 years
Yes
Alexander J. B. McEwan, MB, BS, MSc
Principal Investigator
Cross Cancer Institute
Canada: Health Canada
SP-24513/DX-FLT-002
NCT01065805
February 2009
December 2015
Name | Location |
---|